Mutant Proteins' Unexpected Role in Cancer Progression Unveiled
Researchers at the NIH have discovered a new role for mutant RAS proteins in cancer progression, revealing that they help release the EZH2 protein from a nuclear complex, leading to the breakdown of the tumor suppressor protein DLC1. This finding suggests that combining RAS inhibitors with drugs that reactivate DLC1 could enhance cancer treatment efficacy, particularly in RAS-driven cancers like pancreatic, colorectal, and lung cancers. The study highlights potential new treatment strategies for these aggressive cancers.